Rodin’s The Thinker sculpture Source: Wikimedia Commons
Recently, I have been pondering a raft of clinical and translational data we have seen emerge across multiple virtual conferences from several different categories of therapies such as checkpoint blockade, targeted therapies, PARP inhibition, epigenetics, and even mathematics.
Many people tend to look at these disparate categories and see them as quite different therapeutic options, but lately I have began to wonder if they are in fact much more inextricably linked than seems obvious at first glance?
This turned into a broader strategic post about advanced solid tumours and how we might think a little differently about underlying concepts and conceptual frameworks…
To learn more from our oncology analysis and get a heads up on the latest insights and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
The Francis Crick Institute in London has an admirable program of engagement with the public and external researchers.
Attending a Crick Lecture recently presented by Cancer Research UK (CRUK) Chief Scientific Officer, Prof Karen Vousden CBE FRS, reminded me of my days as a PhD student at nearby King’s College London.
Regular BSB readers will recall that Prof Charles Swanton FRS is the Chief Clinician of CRUK.
In her Crick lecture, Prof Vousden elegantly explained to the audience why p53 mattered and how it might be targeted by small molecules.
What is the potential of this research for translational drug development? In this post, we take a look at new developments in the basic understanding of what p53 does, the current state of targeting p53 and Prof Vousden’s latest approaches.
To learn more from our latest biotech and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.